Literature DB >> 7000337

Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.

B R Brinkley, P T Beall, L J Wible, M L Mace, D S Turner, R M Cailleau.   

Abstract

Cell form and cytoskeletal organization were investigated in 13 human breast carcinoma cell lines in vitro. Using tubulin antibodies and indirect immunofluorescence to detect the arrangement of cytoplasmic microtubules, three distinct cell phenotypes were recognized: (a) cells with extensive arrays of microtubules (type 1); (b) cells which were diffusely stained with microtubules apparent only near the cell margins (type II intermediate); and (c) cells in which individual microtubules could not be detected and only diffuse fluorescence was apparent (type II diffuse). Type I cells were flattened epithelial-like cells, much like normal mammary epithelial cells, which when stained with actin antibody displayed many brightly fluorescent parallel cables or "stress fibers." Many microtubules and microfilament bundles were observed in type I cells when examined by transmission electron microscopy. Type II cells were more rounded, often grew in multilayered colonies, and displayed fewer microtubules and microfilament bundles when examined by either immunofluorescence or electron microscopy. Type II cells ranged from very small rounded cells with diffuse tubulin and actin immunofluorescence (type II diffuse) to more flattened cells in which microtubules and actin cables were observed near the flattened cell margins (type II intermediate). Since all of the cells were derived initially from malignant metastatic lesions and some were tumorigenic when injected into athymic nude mice, we assume that they remained malignant in vitro. Thus, in human breast carcinoma cells in vitro, it is not possible to associate any specific cell morphology or cytoskeletal phenotype with cancer or metastasis in vivo. Whether or not these same conclusions hold for breast tumor cells in situ remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000337

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.

Authors:  Maria Ait-Tihyaty; Zakaria Rachid; Anne-Laure Larroque-Lombard; Bertrand J Jean-Claude
Journal:  Invest New Drugs       Date:  2013-12       Impact factor: 3.850

2.  High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro.

Authors:  Shuya Yano; Kiyoto Takehara; Hiroyuki Kishimoto; Hiroshi Tazawa; Yasuo Urata; Shunsuke Kagawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-01-26       Impact factor: 2.416

3.  Comparison of in vitro invasiveness of high- and low-metastatic triple-negative human breast cancer visualized by color-coded imaging.

Authors:  Shuya Yano; Kiyoto Takehara; Hiroshi Tazawa; Hiroyuki Kishimoto; Shunsuke Kagawa; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-10-24       Impact factor: 2.416

4.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

5.  Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography.

Authors:  C Ryan Oliver; Trisha M Westerhof; Maria G Castro; Sofia D Merajver
Journal:  J Vis Exp       Date:  2020-08-16       Impact factor: 1.355

6.  Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells.

Authors:  H R Soule; E Linder; T S Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.

Authors:  Antonio F Santidrian; Akemi Matsuno-Yagi; Melissa Ritland; Byoung B Seo; Sarah E LeBoeuf; Laurie J Gay; Takao Yagi; Brunhilde Felding-Habermann
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

8.  Development of a new human breast cancer cell line Ia-270.

Authors:  P M Loh; G Clamon; J MacIndoe; M White; L Urdaneta; B Hukku; W D Peterson
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

9.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

10.  Cytotoxicity of Atriplex confertifolia.

Authors:  Christopher J Capua; Nick P Hopson; C Malcolm M Stewart; G Robert Johnston; Kim L O'Neill; G Bruce Schaalje; Christopher M Lee; Gary M Booth
Journal:  J Toxicol       Date:  2010-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.